EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Dexmedetomidine Prevents Chronic Incisional Pain After Brain Tumor Resection: A Secondary Analysis of the Randomized Control Trial

Min Zeng, Xin Xu, Ruowen Li, Xingyue Zhang, Tingting Ma, Qianyu Cui, Juan Wang, Shu Li, Yuming Peng

Anesthesia & Analgesia · 2024

DOI: 10.1213/ane.0000000000006563 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Anesthesia & Analgesia, 2024. Verfasst von Min Zeng und 8 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, People's Republic of China. Hauptthemen laut MEDLINE: Dexmedetomidine, Analgesics, Non-Narcotic, Acute Pain, Brain Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Ministry of Science and Technology of the People's Republic of China funding, Beijing Municipal Science & Technology Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Dexmedetomidine was reported to reduce postoperative acute pain after neurosurgery. However, the efficacy of dexmedetomidine for preventing chronic incisional pain is uncertain. METHODS: This article is a secondary analysis of a randomized, double-blind, placebo-controlled trial. Eligible patients were randomly allocated to either the dexmedetomidine group or the placebo group. Patients assigned to the dexmedetomidine group were given a 0.6 μg kg −1 dexmedetomidine bolus followed by a 0.4 μg kg −1 h −1 maintenance dose until dural closure; placebo patients were given comparable amounts of normal saline. The primary end point was the incidence of incisional pain at 3 months after craniotomy evaluated by numerical rating scale scores and defined as any score >0. The secondary end points were postoperative acute pain scores, sleep quality, and Short-Form McGill Pain Questionnaire (SF-MPQ-2) at 3 months after craniotomy. RESULTS: From January 2021 to December 2021, a total of 252 patients were included in the final analysis: the dexmedetomidine group (n = 128) and the placebo group (n = 124). The incidence of chronic incisional pain was 23.4% (30 of 128) in the dexmedetomidine group versus 42.7% (53 of 124) in the placebo group (risk ratio, 0.55; 95% confidence interval, 0.38–0.80; P = .001). The overall severity of chronic incisional pain was mild in both groups. Patients in the dexmedetomidine group had lower acute pain severity on movement than those in the placebo group for the first 3 days after surgery (all adjusted P < .01). Sleep quality did not differ between groups. However, the SF-MPQ-2 total sensory ( P = .01) and neuropathic pain descriptor ( P = .023) scores in the dexmedetomidine group were lower than those in the placebo group. CONCLUSIONS: Prophylactic intraoperative dexmedetomidine infusion reduces the incidence of chronic incisional pain as well as acute pain score after elective brain tumor resections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DexmedetomidineAnalgesics, Non-NarcoticAcute PainBrain NeoplasmsChronic PainHumansPostoperative PainCraniotomyDouble-Blind Method

Substanzen

DexmedetomidineAnalgesics, Non-Narcotic

Autor:innen und Institutionen

  • From the Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, People's Republic of China.
  • Department of Anesthesiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of Chin…
  • Department of Anesthesiology, China-Japan Friendship Hospital, Beijing, People's Republic of China.

Förderung

  • Ministry of Science and Technology of the People's Republic of China funding
  • Beijing Municipal Science & Technology Commission

Zitieren

APA

Zeng, M., Xu, X., Li, R., Zhang, X., Ma, T., Cui, Q., Wang, J., Li, S., & Peng, Y. (2024). Dexmedetomidine Prevents Chronic Incisional Pain After Brain Tumor Resection: A Secondary Analysis of the Randomized Control Trial. Anesthesia & Analgesia. https://doi.org/10.1213/ane.0000000000006563

Vancouver

Zeng M, Xu X, Li R, Zhang X, Ma T, Cui Q, et al. Dexmedetomidine Prevents Chronic Incisional Pain After Brain Tumor Resection: A Secondary Analysis of the Randomized Control Trial. Anesthesia & Analgesia. 2024. doi:10.1213/ane.0000000000006563

BibTeX
@article{Zeng2024,
  author = {Zeng, Min and Xu, Xin and Li, Ruowen and Zhang, Xingyue and Ma, Tingting and Cui, Qianyu and Wang, Juan and Li, Shu and Peng, Yuming},
  title = {Dexmedetomidine Prevents Chronic Incisional Pain After Brain Tumor Resection: A Secondary Analysis of the Randomized Control Trial},
  journal = {Anesthesia & Analgesia},
  year = {2024},
  doi = {10.1213/ane.0000000000006563}
}
Kostenlos starten →